Barclays Maintains Overweight on Sutro Biopharma, Raises Price Target to $57
Benzinga Newsdesk 6 days ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Barclays analyst Lukas Shumway maintains Sutro Biopharma (NASDAQ:STRO) with a Overweight and raises the price target from $56 to $57.
Barclays analyst Lukas Shumway maintains Sutro Biopharma (NASDAQ:STRO) with a Overweight and raises the price target from $56 to $57.
